The multiple tyrosine kinases inhibitor cabozantinib has shown improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in comparison to everolimus in patients with metastatic renal cell carcinoma (mRCC) in the METEOR trial, a phase III, randomized, open-label trial [1,2], leading to its approval in mRCC patients previously treated with antiangiogenic agents.
Raffaele Ratta, Daniele Santini, Elena Verzoni and Giuseppe Procopio
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : July 15, 2019